Glioblastoma cell membrane

The glioblastoma cell membrane represents the primary interface between the malignant glioma cell and the surrounding neural microenvironment, playing a pivotal role in tumor invasion, metabolic adaptation, and therapeutic resistance (PMID: 31434060). It is characterized by a distinct 'surfaceome' featuring overexpressed or mutated proteins such as EGFRvIII, IL-13Rα2, and various integrins, which are absent or minimally expressed in healthy brain tissue (PMID: 33806305). Beyond protein components, the membrane's lipid composition, including enriched cholesterol and sphingolipids, facilitates the formation of lipid rafts that organize oncogenic signaling complexes (PMID: 30232151). While the membrane itself is a broad cellular structure rather than a single molecular entity, it serves as the essential docking site for a wide array of targeted therapies, including monoclonal antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cells (PMID: 28819281). However, the extreme intratumoral heterogeneity and the restrictive nature of the blood-brain barrier remain significant hurdles for effectively targeting membrane-associated antigens in glioblastoma (PMID: 30545811). Furthermore, the dynamic remodeling of the membrane in response to treatment can lead to antigen escape, necessitating the development of multi-targeted or combinatorial approaches to achieve durable clinical responses.

Other names

GBM plasma membraneGlioblastoma multiforme cell surfaceGlioblastoma cell surface

Therapeutic strategies targeting the glioblastoma cell membrane involve the use of monoclonal antibodies or small molecules to inhibit surface receptor signaling, the deployment of CAR-T cells to recognize and lyse cells expressing specific surface antigens, and the use of membrane-active peptides or nanoparticles to disrupt lipid bilayer integrity or deliver intracellular payloads (PMID: 31434060, PMID: 33806305).